San Francisco, CA, United States of America

Malcolm Huestis

USPTO Granted Patents = 8 

Average Co-Inventor Count = 10.3

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • San Francisco, CA (US) (2016 - 2021)
  • South San Francisco, CA (US) (2018 - 2021)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
8 patents (USPTO):

Title: The Innovative Contributions of Malcolm Huestis

Introduction

Malcolm Huestis is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating various diseases. With a total of 8 patents to his name, Huestis has established himself as a key figure in innovation.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Lactams as CBL-B inhibitors selective over C-CBL." This compound is designed for treating cancers that are susceptible to inhibition of Cbl-B. Another notable patent is for "Biheteroaryl compounds and uses thereof," which provides compounds for the treatment of neurodegenerative diseases. These inventions showcase Huestis's commitment to advancing medical science.

Career Highlights

Malcolm Huestis is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to focus on creating impactful solutions for complex health issues.

Collaborations

Huestis has collaborated with several talented individuals in his field, including Michael Siu and Snahel Patel. These partnerships have contributed to the success of his projects and the advancement of their shared goals.

Conclusion

Malcolm Huestis's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for innovative treatments that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…